STOCK TITAN
  1. Home
  2. Sec-filings
  3. RLMD
  4. [Form 4] RELMADA THERAPEUTICS, INC. Insider Trading Activity

Relmada Therapeutics (RLMD) officer receives 828K stock appreciation rights

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities

Positive

  • None.

Negative

  • None.
Insider Ence Chuck
Role CA and CO
Type Security Shares Price Value
Grant/Award Stock Appreciation Rights 828,000 $0.00 --
Holdings After Transaction: Stock Appreciation Rights — 828,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ence Chuck
(Last) (First) (Middle)
C/O RELMADA THERAPEUTICS, INC.
2222 PONCE DE LEON BLVD, 3RD FLOOR
(Street)
CORAL GABLES FL 33134
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CA and CO
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Rights $4.06 12/12/2025 A 828,000 03/12/2026(1) 12/12/2035 Common Stock 828,000 $0 828,000 D
Explanation of Responses:
1. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
/s/ Chuck Ence 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Relmada Therapeutics (RLMD) report in this Form 4?

The company reported that an officer received 828,000 stock appreciation rights12/12/2025

What is the exercise price and term of the new stock appreciation rights at Relmada Therapeutics (RLMD)?

The stock appreciation rights have an exercise price of $4.0612/12/203503/12/2026

How do the Relmada Therapeutics (RLMD) stock appreciation rights vest for this officer?

The stock appreciation rights vest in 16 equal quarterly installmentsMarch 12, 2026, as disclosed in the explanation of responses.

How many derivative securities does the Relmada Therapeutics (RLMD) officer own after this transaction?

Following the reported transaction, the officer beneficially owns 828,000 derivative securitiesdirectly.

What common stock is underlying the Relmada Therapeutics (RLMD) stock appreciation rights grant?

The stock appreciation rights are linked to 828,000 sharesRelmada Therapeutics common stock